MicroRNA expression profiling in peritoneal fibrosis

Area of Science:

• Biochemistry
• Molecular Biology
• Nephrology

Background:

• Peritoneal fibrosis (PF) is a severe complication of peritoneal dialysis (PD), often leading to membrane failure.
• Identifying the molecular mechanisms underlying PF is crucial for developing effective treatments.

Purpose of the Study:

• To identify microRNAs (miRNAs) involved in the pathogenesis of peritoneal fibrosis (PF).
• To evaluate the diagnostic potential of identified miRNAs as biomarkers for PF.
• To investigate the therapeutic efficacy of targeting specific miRNAs in PF.

Main Methods:

• Microarray analysis of miRNA expression in rat peritoneal tissue models of PF.
• Quantification of miRNA levels in serum and dialysate from PD patients.
• Correlation analysis of miRNA levels with peritoneal membrane function (peritoneal equilibrium test).
• In vivo study using miRNA inhibitors (anti-miRNA-21-5p locked nucleic acid) in a mouse model of PF.

Main Results:

• Six miRNAs (miRNA-142-3p, miRNA-21-5p, miRNA-221-3p, miRNA-223-3p, miRNA-34a-5p, and miRNA-327) showed increased expression in PF rat models.
• Serum levels of miRNA-21-5p, miRNA-221-3p, and miRNA-327, and dialysate levels of miRNA-221-3p and miRNA-34a-5p correlated significantly with peritoneal membrane function in PD patients.
• Intraperitoneal administration of anti-miRNA-21-5p locked nucleic acid inhibited PF, reduced peritoneal thickening, and preserved membrane function in mice.

Conclusions:

• Several miRNAs are significantly involved in the development of peritoneal fibrosis (PF).
• Specific miRNAs (miRNA-21-5p, miRNA-221-3p, miRNA-327, miRNA-34a-5p) show potential as diagnostic biomarkers for PF in PD patients.
• Targeting miRNA-21-5p offers a potential therapeutic strategy for managing PF and improving peritoneal dialysis outcomes.